Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laith J Abu-Raddad

Showing results (301-310 of 318) with videos related to

Pageof 32
Sort By:
Nature Medicine|July 10, 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in QatarHiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, et al.
Frontiers in Immunology|February 23, 2023
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid <i>ex-vivo</i> T cells expansion protocol for adoptive immunotherapy: A pilot studySarra Mestiri, Maysaloun Merhi, Varghese P Inchakalody, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 17, 2023
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort studyHiam Chemaitelly, Jeremy Samuel Faust, Harlan M Krumholz, et al.
Plos One|January 31, 2022
Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2Peter V Coyle, Reham Awni El Kahlout, Soha R Dargham, et al.
Iscience|May 31, 2021
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individualsPeter V Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
Lancet (London, England)|July 11, 2016
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Jeffrey D Stanaway, Abraham D Flaxman, Mohsen Naghavi, et al.
Frontiers in Cellular and Infection Microbiology|December 6, 2021
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in QatarFatiha M Benslimane, Hebah A Al Khatib, Ola Al-Jamal, et al.
Emerging Infectious Diseases|April 26, 2021
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, QatarAndrew Jeremijenko, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature|November 4, 2022
A multinational Delphi consensus to end the COVID-19 public health threatJeffrey V Lazarus, Diana Romero, Christopher J Kopka, et al.
Open Forum Infectious Diseases|August 30, 2021
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of QatarMohamed H Al-Thani, Elmoubasher Farag, Roberto Bertollini, et al.
Pageof 32

Showing results (301-310 of 318) with videos related to

Sort By:
Pageof 32
Nature Medicine|July 10, 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in QatarHiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, et al.
Frontiers in Immunology|February 23, 2023
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid <i>ex-vivo</i> T cells expansion protocol for adoptive immunotherapy: A pilot studySarra Mestiri, Maysaloun Merhi, Varghese P Inchakalody, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 17, 2023
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort studyHiam Chemaitelly, Jeremy Samuel Faust, Harlan M Krumholz, et al.
Plos One|January 31, 2022
Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2Peter V Coyle, Reham Awni El Kahlout, Soha R Dargham, et al.
Iscience|May 31, 2021
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individualsPeter V Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
Lancet (London, England)|July 11, 2016
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Jeffrey D Stanaway, Abraham D Flaxman, Mohsen Naghavi, et al.
Frontiers in Cellular and Infection Microbiology|December 6, 2021
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in QatarFatiha M Benslimane, Hebah A Al Khatib, Ola Al-Jamal, et al.
Emerging Infectious Diseases|April 26, 2021
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, QatarAndrew Jeremijenko, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature|November 4, 2022
A multinational Delphi consensus to end the COVID-19 public health threatJeffrey V Lazarus, Diana Romero, Christopher J Kopka, et al.
Open Forum Infectious Diseases|August 30, 2021
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of QatarMohamed H Al-Thani, Elmoubasher Farag, Roberto Bertollini, et al.
Pageof 32